LLYX

LLYX uses swap agreements to make bullish bets on Eli Lilly and Company's (NYSE:LLY) share price. LLY is a global pharmaceutical company dedicated to discovering, developing, manufacturing, and marketing innovative medicines in various therapeutic areas, including neuroscience, endocrinology, oncology, cardiovascular diseases, and immunology. The fund maintains a daily leveraged exposure equivalent to 200% of the fund's net assets through daily rebalancing. As a geared product, the fund is intended as a short-term tactical tool, rather than as a long-term investment vehicle. As a result, returns may deviate from the expected 2x if held for longer than a single day due to compounding. This strategy is high-risk and does not include a defensive position as part of its overall process. Additionally, the fund could potentially lose money over time, even if LLY's performance strengthens. The fund is expected to invest in cash-like instruments as collateral.